OakChart

DBV Technologies ADR

DBVTHealthcare·Biotechnology·France·Small·NASD·Nov 11 • 7:56 AM ET

11.65+0.14 (1.22%)
2026-11-11 14:43 CET
Market cap
723.30 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-207.33 USD m
Free cash flow, TTM
-191.84 USD m
EPS diluted, TTM
-3.02
P/E
-
Compare

Price

DBVT against its 20, 50 and 200-day averages
2050200miss
10.0015.0020.001.3M2.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DBVTclose 11.6520-day 9.9950-day 10.93200-day 16.4811.65

55.5% under 26.19 on 17 Dec 2025. Last 15 sessions, 30.5% high to low

Profile

DBVT
52-week range, 17% of the way up
8.6326.18

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

Employees125
IPOOct 22, 2014
Beta-0.88
ATR, 14d0.68
Rel volume0.06
Short float1.49%
Insider own13.77%
Inst own25.80%

Snapshot

6 groups

Valuation

Index-
Market Cap732.09M
Enterprise Value588.59M
Income-207.33M
Sales0.00M
Book/sh2.36
Cash/sh2.64
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees125
IPOOct 22, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.93
P/C4.42
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.24
Current Ratio3.24
Debt/Eq0.15
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.02
EPS next Y-0.70
EPS next Q-0.23
EPS this Y-8.03%
EPS next Y38.29%
EPS next 5Y45.77%
EPS past 3/5Y5.33% 18.68%
Sales past 3/5Y- -
EPS Y/Y TTM42.37%
Sales Y/Y TTM-
EPS Q/Q40.80%
Sales Q/Q-
EarningsOct 28 AMC
EPS/Sales Surpr.46.15% 220.00%

Ownership

Insider Own13.77%
Insider Trans-0.01%
Inst Own25.80%
Inst Trans48.41%
ROA-127.24%
ROE-205.84%
ROIC-133.50%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2016.64%
SMA506.57%
SMA200-29.33%
Trades-

Technical

Shs Outstand62.84M
Shs Float54.18M
Short Float1.49%
Short Ratio2.33
Short Interest0.81M
52W High26.18 -55.51%
52W Low8.63 34.99%
Volatility8.43% 6.73%
ATR (14)0.68
RSI (14)62.53
Beta-0.88
Rel Volume0.06
Avg Volume346.75K
Volume1,050

Performance

Perf Week17.20%
Perf Month29.01%
Perf Quarter-16.96%
Perf Half Y-40.56%
Perf YTD-39.23%
Perf Year-12.67%
Perf 3Y22.62%
Perf 5Y-63.48%
Perf 10Y-96.83%
Recom1.00
Target Price41.92
Prev Close11.51
Price11.65
Change %1.22%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Dec 15, 2025InitiatedCCantor FitzgeraldOverweight$42+260.5%
Dec 03, 2025InitiatedGGuggenheimBuy$35+200.4%
May 29, 2025ResumedGGoldmanSell$7.25-37.8%
Jan 04, 2023UpgradeSSociete GeneraleHold → Buy
Dec 16, 2022DowngradeGGoldmanNeutral → Sell
May 10, 2022DowngradeGGoldmanBuy → Neutral$6 → $1.50-87.1%
Sep 14, 2021UpgradeSSociete GeneraleHold → Buy
Jan 22, 2021DowngradeSSociete GeneraleHold → Sell
Nov 02, 2020UpgradeSSociete GeneraleSell → Hold
Aug 06, 2020DowngradeSSociete GeneraleBuy → Sell

Peers

Mkt cap
TickerCompanyMkt cap
PHVSPharvaris NV2.39B
ACRSAclaris Therapeutics Inc609.28M
UPBUpstream Bio Inc185.13M
EVMNEvommune Inc287.07M
ALMSAlumis Inc862.38M
ARQTArcutis Biotherapeutics Inc3.48B
ANABAnaptysBio Inc1.45B
CNTBConnect Biopharma Holdings Ltd44.07M
VRCAVerrica Pharmaceuticals Inc60.47M
JSPRJasper Therapeutics Inc16.36M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Mohideen PharisChief Medical OfficerJul 29 '26Sale2.704641,253144,531Jul 31 04:15 PM
Mohideen PharisChief Medical OfficerJan 29 '26Sale4.865342,595144,995Feb 02 04:30 PM
EPIC BpifranceMember of 10% owner groupDec 17 '25Sale4.852,076,99010,070,2328,595,472Dec 19 04:04 PM
EPIC BpifranceMember of 10% owner groupDec 18 '25Sale4.191,292,1035,413,9127,303,369Dec 19 04:04 PM
Mohideen PharisChief Medical OfficerNov 20 '25Sale2.886,49618,708103,153Nov 25 04:15 PM
Mohideen PharisChief Medical OfficerNov 21 '25Sale2.771,6244,498101,529Nov 25 04:15 PM

Held by

AUM
TickerCompanyAUM
APIEActivePassive International Equity ETFAUM: 1.13B

News

latest 14 of 206
  • DBV Technologies to Participate in Upcoming November Investor Conferences (GlobeNewswire) +11.71%
  • DBV Technologies shares slide 8% on going-concern warning, wider Q3 loss (Investing.com)
  • DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update (GlobeNewswire) +5.19%
  • DBV Technologies Must Prove Its Peanut Patch BLA Landed On Schedule As Shares Slump (Earnings Whispers)
  • DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 (GlobeNewswire)
  • Loading…
  • DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years (GlobeNewswire)
  • DBV Technologies to Participate in Upcoming September Investor Conferences (GlobeNewswire)
  • Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (GlobeNewswire)
  • DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq (GlobeNewswire)
  • DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales (GlobeNewswire)
  • DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the Report (GlobeNewswire) -5.41%
  • DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update (GlobeNewswire)
  • DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-28-0.140-0.260-0.1401.600.501
2026Q22026-07-16-0.120-0.108-0.5800.700.785
2026Q12026-04-30-0.110-0.134-0.5580.900.955
2025Q42026-03-26-0.240-0.178-1.1700.501.276
2025Q32025-10-28-0.240-0.318-1.2072.800.884
2025Q22025-07-29-0.310-0.180-1.5781.500.733
2025Q12025-04-30-0.260-0.240-1.3200.800.501
2024Q42025-03-24-0.240-0.220-1.1390.601.101
2024Q32024-11-06-1.600-1.800-1.5871.101.142
2024Q22024-07-30-1.700-2.234-1.7201.201.683
2024Q12024-05-07-2.800-2.100-1.4181.402.263
2023Q42024-03-07-1.100-2.300-0.5868.861.173
2023Q32023-10-31-1.700-2.367-0.8672.401.303
2023Q22023-07-31-2.600-2.134-1.2842.300.913
2023Q12023-05-04-2.200-2.067-1.0992.201.203
2022Q42023-03-02-4.100-2.150-2.106-1.301.422

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-23.118-35.702-23.23614.5913.36
2020FY-29.500-22.765-14.84611.2813.20
2021FY-17.800-16.180-8.8845.715.37
2022FY-12.400-8.267-6.2244.806.13
2023FY-6.333-6.197-3.82915.726.63
2024FY-1.170-1.160-5.8624.202.35
2025FY-1.050-1.303-1.0505.605.56
2026FY--1.134--3.22
2027FY--0.700--66.00
2028FY--0.168--279.09
2029FY-0.215--624.01
2030FY-0.623--993.61

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-294000.630.001.00
2026Q4S2026-10-281000.500.500.50
2026Q4S2026-10-252000.660.500.82
2026Q4S2026-10-035000.660.001.00
2026Q4S2026-07-205010.660.001.00
2026Q4S2026-07-175000.780.001.39
2026Q4S2026-07-155000.780.001.39
2026Q4S2026-05-015210.780.001.39
2026Q4S2026-04-075000.940.002.00
2026Q4S2026-03-274000.860.002.00
2026Q4S2025-12-123000.830.002.00
2026Q4S2025-12-022001.250.502.00
2026Q4S2025-11-111000.500.500.50
2026Q4S2025-11-101000.500.500.50

Estimate history

EPS, annual-33.669-33.868-23.236-14.846-8.884-6.224-3.829-5.862-5.28-3.022
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.587-1.139-1.32-1.578-1.207-1.17-0.558-0.58-0.714
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual4.9986.0239.39710.96511.01918.79719.24220.51647.11962.841
Period201720182019202020212022202320242025MRQ
Shares, quarterly19.24120.51620.52627.35327.36347.11959.18359.18362.841
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A17.7817.676.81-4.5021.3510.9417.613.054.97
Gross Profit-17.78-17.67-6.814.50-21.35-10.94-17.61-3.05-4.97
Selling, General and Administrative Excl. Other194.22135.49113.7196.8180.1893.78129.93182.65208.26
Research and Development137.27107.1289.9074.0062.6169.9985.46112.22123.50
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-212.00-153.16-120.53-92.30-101.53-104.73-147.54-185.70-213.23
Interest Expense-----0.690.730.380.41
Unusual Expense0.000.000.000.000.00-0.9223.710.00-
Net Income Before Taxes-210.10-152.56-117.80-81.61-101.98-105.77-170.62-182.30-208.93
Income Taxes-2.77-5.16-4.08-8.77-5.65-7.87-10.01-10.33-13.00
Consolidated Net Income-207.33-147.40-113.72-72.84-96.33-97.90-160.61-171.98-195.93
Net Income From Continuing Operations-207.33-147.40-113.72-72.84-96.33-97.90-160.61-171.98-195.93
Net Income-207.33-147.40-113.72-72.84-96.33-97.90-160.61-171.98-195.93
EPS (Recurring)-2.30-5.28-5.86-3.83-6.22-8.94-13.31-23.24-33.87
EPS (Basic, Before Extraordinaries)-3.02-5.28-5.86-3.83-6.22-8.88-14.85-23.24-33.87
EPS (Diluted)-3.02-5.28-5.86-3.83-6.22-8.88-14.85-23.24-33.87
EBITDA-194.22-135.49-113.71-96.81-80.18-93.78-129.93-182.65-208.26
Non-Operating Income (Expense)2.100.602.7310.69-0.45-1.271.363.774.71
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.114.273.644.763.972.28-0.8211.8920.37
Shares Outstanding62.8447.1220.5219.2418.8011.0210.979.406.02
Market Capitalization723.30723.3063.38183.09287.30175.81287.541,006.22386.70

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.605.694.224.284.284.624.480.00
Gross Profit-3.60-5.69-4.22-4.28-4.28-4.62-4.480.00
Selling, General and Administrative Excl. Other62.6445.5444.6641.3832.6038.5222.9124.20
Research and Development46.9528.9631.3130.0426.8231.6218.6018.77
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-66.23-51.23-48.88-45.66-36.88-43.14-27.39-24.20
Interest Expense-----0.660.46-
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-65.73-50.83-48.48-45.07-35.78-43.80-27.85-23.35
Income Taxes-1.30-0.50-0.70-0.27-2.76-1.37-0.75-0.50
Consolidated Net Income-64.43-50.33-47.77-44.80-33.01-42.44-27.10-22.85
Net Income From Continuing Operations-64.43-50.33-47.77-44.80-33.01-42.44-27.10-22.85
Net Income-64.43-50.33-47.77-44.80-33.01-42.44-27.10-22.85
EPS (Recurring)-0.71-0.58-0.56-1.17-1.21-1.58-1.32-1.14
EPS (Basic, Before Extraordinaries)-0.71-0.58-0.56-1.17-1.21-1.58-1.32-1.14
EPS (Diluted)-0.71-0.58-0.56-1.17-1.21-1.58-1.32-1.14
EBITDA-62.64-45.54-44.66-41.38-32.60-38.52-22.91-23.56
Non-Operating Income (Expense)0.600.400.500.601.110.000.000.85
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.952.921.731.520.411.001.70-
Shares Outstanding62.8459.1859.1847.1227.3627.3520.5320.52
Market Capitalization723.30970.661,162.70769.45273.53250.47139.8863.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments194.1732.46141.37209.1977.30196.35193.25140.34165.57
Short Term Receivables16.1510.3915.4511.2033.077.865.4119.2820.33
Inventories0.000.000.000.000.000.002.291.790.00
Other Current Assets2.631.542.102.684.153.163.604.882.47
Total Current Assets212.9444.39158.91223.07114.52207.37204.55166.29188.36
Net Property, Plant & Equipment14.9416.8117.8717.6124.9234.9048.6023.1121.38
Total Investments and Advances0.620.114.074.053.974.585.126.402.01
Intangible Assets0.020.040.060.010.020.040.050.030.15
Other Assets5.194.312.071.772.9025.3513.410.000.00
Total Assets233.7265.66182.99246.52146.32272.25271.73195.84211.91
Short Term Debt Incl. Current Port. of LT Debt16.278.799.858.903.514.434.331.372.79
Accounts Payable40.9422.0323.3014.4711.4320.3424.000.000.00
Income Tax Payable0.590.190.220.070.180.580.430.510.51
Other Current Liabilities0.220.123.966.0816.2727.3625.2347.8939.84
Total Current Liabilities58.0231.1437.3429.5231.4052.7154.0049.7843.14
Long Term Debt5.416.304.531.137.1511.0422.801.462.19
Provision for Risks Charges0.000.000.000.000.000.000.001.761.51
Other Liabilities1.510.840.9421.428.753.001.744.6910.65
Total Liabilities64.9538.2742.8052.0647.2966.7578.5457.6957.50
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity168.7727.39140.19194.4599.03205.49193.19138.15154.41
Total Shareholders Equity168.7727.39140.19194.4599.03205.49193.19138.15154.41
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity168.7727.39140.19194.4599.03205.49193.19138.15154.41
Total Liabilities & Stockholders Equity233.7265.66182.99246.52146.32272.25271.73195.84211.91
Book Value Per Share3.581.337.2910.348.9918.7420.5622.9430.89
Tangible Book Value Per Share3.581.337.2810.348.9818.7420.5522.9330.86
Full-Time Employees1251091048592141319315242
Price to Book Ratio4.871.101.271.351.771.145.262.805.60
Return on Assets-98.47-91.47-33.92-48.99-46.78-59.25-73.56-96.10-64.85
Return on Equity-150.29-135.72-43.53-65.59-64.30-80.94-103.81-133.94-81.43
Return on Invested Capital-84.63-337.60-50.33-49.25-92.20-74.18-79.62-140.33-106.38
Quick Ratio3.671.434.267.563.653.933.753.304.37
Current Ratio3.671.434.267.563.653.933.793.344.37

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-207.44-147.40-113.72-72.84-96.33-97.90-160.61-171.98-195.93
Depreciation2.793.20-0.92-14.0213.1710.9417.613.053.34
Other Funds (Non Cash)24.0221.304.616.135.134.61-7.9917.1631.80
Funds from Operations-180.62-122.90-110.03-80.73-78.03-82.34-151.00-151.77-160.79
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-7.841.345.740.9522.33-21.55-15.713.45-0.38
Cash from Operating Activities-188.46-121.56-104.29-79.78-55.70-103.90-166.70-148.32-161.18
Capital Expenditures-3.38-0.54-2.34-0.68-0.75-0.92-2.78-5.60-5.60
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.010.600.000.00-
Purchase or Sale of Investments0.000.000.00-0.130.65-0.12-0.10-0.06-4.59
Purchase of Investments0.000.000.00-0.29-0.12-0.12-0.10-0.06-4.59
Sale Or Maturity of Investments0.000.000.000.150.770.000.000.000.00
Other Uses-3.54-0.830.000.000.000.000.000.000.00
Other Sources0.000.001.580.000.000.000.000.00-
Cash from Investing Activities-6.92-1.37-0.76-0.81-0.10-0.43-2.88-5.66-10.19
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock296.29277.040.596.78194.700.98150.88208.90156.46
Repurchase of Common Pref Stock-0.200.00-0.05-0.150.000.00-0.570.00-0.57
Sale of Common Pref Stock296.49277.040.636.93194.700.98151.45208.90157.02
Proceedsfrom Stock Options159.43277.040.636.93194.700.98151.45208.90157.02
Issuance or Reduction of Debt, Net0.000.000.000.00-0.47-0.69-0.31-1.32-2.12
Change in Long Term Debt0.000.000.000.00-0.47-0.69---
Issuance of Long Term Debt0.000.000.000.000.000.00---
Reduction of Long Term Debt0.000.000.000.00-0.47-0.69---
Net Financing Active Other Cash Flow0.200.000.000.000.00-4.19-0.04-0.04-0.17
Other Financing Activities Uses0.000.000.000.000.00-4.19-0.04-0.04-0.17
Cash from Financing Activities296.59277.040.596.78194.23-3.90150.54207.54154.16
Exchange Rate Effect-5.058.10-4.265.88-6.46-10.6322.17-0.89-0.62
Net Change in Cash96.16162.21-108.72-67.93131.97-118.863.1252.67-17.83
Free Cash Flow-191.84-122.09-106.62-80.45-56.45-104.80-169.45-153.89-166.73
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments165.70174.90229.20194.1769.84103.21
Short Term Receivables19.7017.3015.1016.1515.9715.69
Inventories0.000.000.000.000.000.00
Other Current Assets4.209.602.402.633.072.34
Total Current Assets189.60201.80246.70212.9488.88121.24
Net Property, Plant & Equipment17.0015.6014.1014.9416.1316.83
Total Investments and Advances0.400.600.000.620.000.00
Intangible Assets--0.100.020.020.03
Other Assets8.305.205.405.195.465.33
Total Assets215.40223.20266.40233.72110.50143.43
Short Term Debt Incl. Current Port. of LT Debt15.5014.1011.2016.279.317.89
Accounts Payable13.8011.8039.5040.9439.8240.79
Income Tax Payable0.600.600.600.590.140.62
Other Current Liabilities28.6027.800.500.220.220.12
Total Current Liabilities58.5054.3051.8058.0249.4849.42
Long Term Debt6.706.905.105.416.696.70
Provision for Risks Charges1.501.601.600.000.000.00
Other Liabilities0.000.000.001.511.471.08
Total Liabilities66.7062.8058.5064.9557.6457.21
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity148.60160.40207.90168.7752.8586.22
Total Shareholders Equity148.60160.40207.90168.7752.8586.22
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity148.60160.40207.90168.7752.8586.22
Total Liabilities & Stockholders Equity215.30223.20266.40233.72110.50143.43
Book Value Per Share2.362.713.513.581.933.15
Tangible Book Value Per Share2.362.713.513.581.933.15
Full-Time Employees---125--
Price to Book Ratio4.874.675.839.923.1765.44
Return on Assets-127.24-95.96-106.02-98.43-123.21-95.42
Return on Equity-205.84-142.66-159.43-150.23-234.64-148.70
Return on Invested Capital-41.49-30.08-22.43-25.72-55.45-45.67
Quick Ratio3.243.724.763.671.802.45
Current Ratio3.243.724.763.671.802.45

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-64.48-50.32-47.77-44.86-33.03-42.43
Depreciation0.600.600.900.690.790.77
Other Funds (Non Cash)9.706.295.222.824.177.86
Funds from Operations-54.18-43.43-41.65-41.36-28.07-33.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.71-9.09-7.636.16-4.29-0.54
Cash from Operating Activities-51.47-52.52-49.28-35.19-32.36-34.33
Capital Expenditures-2.20-0.40-0.40-0.38-0.12-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-3.10-0.100.00-0.34-0.12-0.01
Other Sources0.00-0.200.200.000.000.00
Cash from Investing Activities-5.30-0.60-0.30-0.72-0.24-0.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock47.77-0.1489.22159.43-0.33117.88
Repurchase of Common Pref Stock-0.200.20-0.200.000.000.00
Sale of Common Pref Stock47.97-0.3489.42159.43-0.33117.88
Proceedsfrom Stock Options0.000.000.00159.43-0.33117.88
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.200.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities48.07-0.1489.22159.43-0.33117.88
Exchange Rate Effect-0.60-1.09-4.521.15-0.867.30
Net Change in Cash-9.29-54.3535.13124.68-33.7890.81
Free Cash Flow-53.67-52.92-49.68-35.57-32.48-34.37

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 4.15M 2025: 5.64M
France2024: 4.15M 2025: 5.64M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.49%0.8M54.2M369.42K
2026-10-151.61%0.9M54.2M350.71K
2026-09-302.07%1.1M54.2M309.13K
2026-09-152.50%1.4M54.2M321.14K
2026-08-312.95%1.6M53.7M296.33K
2026-08-143.04%1.6M53.7M314.25K
2026-07-313.57%1.8M51.8M279.86K
2026-07-153.02%1.5M48.8M248.06K
2026-06-302.66%1.3M48.8M260.05K
2026-06-152.92%1.4M48.8M237.15K
2026-05-293.47%1.7M48.1M250.03K
2026-05-153.74%1.8M48.1M230.12K
2026-04-303.66%1.8M49.6M258.67K
2026-04-153.22%1.6M49.3M323.04K
2026-03-313.60%1.7M46.9M343.33K
2026-03-133.19%1.5M46.9M448.28K
2026-02-272.83%1.3M46.9M510.70K
2026-02-132.66%1.2M46.3M509.37K
2026-01-303.78%1.3M33.2M467.18K
2026-01-153.77%1.2M33.2M394.27K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call5.004.007.700.007.3110.000.000.902-0.1210.003
call7.501.505.902.506.0001.000.000.902-0.2220.003
call10.000.005.000.556.2322800.000.796-0.2420.005
call12.500.000.950.401.7681300.000.473-0.0800.008
call15.000.005.000.052.6623.000.000.350-0.0950.007
call17.500.005.000.753.3001.000.000.308-0.1120.007
call20.000.005.000.903.8004.000.000.284-0.1240.006
call22.500.005.000.004.2150.000.000.267-0.1330.006
call25.000.005.000.004.5670.000.000.255-0.1410.006
put5.000.005.000.000.0000.000.00-0.097-0.1150.003
put7.500.005.000.1013.4063070.00-0.098-0.2210.003
put10.000.005.001.518.8771.000.00-0.204-0.2410.005
put12.500.255.001.455.9527.000.00-0.527-0.0790.008
put15.001.606.000.004.7890.000.00-0.650-0.0930.007
put17.504.108.500.005.4710.000.00-0.692-0.1100.007
put20.006.8011.000.006.0120.000.00-0.716-0.1220.006
put22.509.0013.500.006.4620.000.00-0.733-0.1310.006
put25.0011.7016.000.006.8450.000.00-0.745-0.1380.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-09-308-KCurrent report2026-09-29SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-06SCHEDULE 13GSEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-27S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-07-1610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-168-KCurrent report2026-07-16SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-058-KCurrent report2026-06-03SEC
2026-06-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-038-KCurrent report2026-06-03SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-12SCHEDULE 13G/ASEC
2026-05-11ARSAnnual report to security holders. 2025-12-31SEC
2026-05-11DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-03SEC
2026-05-05SCHEDULE 13G/ASEC
2026-05-058-KCurrent report2026-04-30SEC
2026-05-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-01PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-03SEC
2026-04-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-3010-K/A2025-12-31SEC
2026-04-163Initial statement of beneficial ownership of securities2025-10-30SEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-03-028-KCurrent report2026-02-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07001.25K1
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-01002.60K1
2025-120015.48M2
2025-110023.21K2

Institutional holders

Manager% owned
MPM BioImpact LLC6.19%
Siren, L.L.C.3.14%
Vivo Capital, LLC3.12%
PERCEPTIVE ADVISORS LLC2.79%
BAKER BROS. ADVISORS LP2.47%
Artisan Partners Limited Partnership2.32%
UBS Group AG2.28%
Patient Square Capital LP1.76%
MORGAN STANLEY1.61%
Logos Global Management LP1.55%

Funds

Fund% owned
Artisan International Small-Mid Fund1.42%
Fidelity Advisor Biotechnology Fund0.72%
Tax-Managed U.S. Mid & Small Cap Fund0.08%
AdvisorShares Dorsey Wright ADR ETF0.07%
U.S. Small Cap Equity Fund0.04%
U.S. Small Cap Equity Fund0.01%
ActivePassive International Equity ETF0.01%
Steward Values Enhanced International Fund0.01%
Lord Abbett Health Care Fund0.01%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. DBVT. Cached 15 minutes.